Concert Pharmaceuticals to Present CTP-543 Phase 2 Interim Data in Alopecia Areata at 2019 World Congress for Hair Research Annual Meeting

LEXINGTON, Mass.–(BUSINESS WIRE)–lt;a href="https://twitter.com/search?q=%24CNCE&src=ctag" target="_blank"gt;$CNCElt;/agt; lt;a href="https://twitter.com/hashtag/CNCE?src=hash" target="_blank"gt;#CNCElt;/agt;–Concert
Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that interim
clinical data from its CTP-543 Phase 2 trial in alopecia areata will be
presented in a poster presentation and a sponsored lecture at the 11^th
Annual World Congress for Hair Research (WCHR) being held April 24-27,
2019 in Sitges, Barcelona. The details of the presentations are as
follows:

Poster Presentation

• Title: CTP-543, A JAK1/JAK2 Inhibitor, Achieves Primary
  Endpoint in Interim Analysis of Phase 2 Trial in Alopecia Areata
• Date and Time: Thursday, April 25, 2019 at 11:00 a.m. GMT
• Poster Number: P6
• Location: Exhibition Area

Lecture Series

• Title: JAK Inhibitor CTP-543: Interim Results from a Phase 2
  Trial in Alopecia Areata
• Date and Time: Thursday, April 25, 2019, 4:15 – 4:45 p.m. GMT
• Session: Sponsored Lecture
• Room: Auditori

About CTP-543
CTP-543 was discovered by applying Concert’s
deuterium chemistry technology to modify ruxolitinib, a drug which
inhibits Janus kinases 1 and 2 (JAK1 and JAK2) and is commercially
available under the name Jakafi® in the United States for the treatment
of certain blood disorders. Deuterium modification of ruxolitinib was
found to alter its human pharmacokinetics in ways which may enhance its
use as a treatment for alopecia areata. The U.S. Food and Drug
Administration (FDA) has granted Fast Track designation for CTP-543.

About Alopecia Areata
Alopecia areata is an autoimmune
disease that results in partial or complete loss of hair on the scalp
and body that may affect up to 650,000 Americans at any given time¹.
The scalp is the most commonly affected area, but any hair-bearing site
can be affected alone or together with the scalp. Onset of the disease
can occur throughout life with the majority of patients initially having
symptoms by age 40. It is believed to equally affect both women and men.
Alopecia areata can be associated with serious psychological
consequences, including anxiety and depression. There are currently no
drugs approved by the FDA for the treatment of alopecia areata.

Following the FDA’s Patient-Focused Drug Development meeting held in
September 2017 on alopecia areata, the FDA summarized the input shared
by patients and patient representatives in a Voice
of the Patient report. Additional information on the PFDDI is
available online.

About Concert
Concert
Pharmaceuticals is a clinical stage biopharmaceutical company
focused on applying its DCE
Platform® (deuterated chemical entity platform) to create novel
medicines designed to treat serious diseases and address unmet patient
needs. The Company’s approach starts with previously studied compounds,
including approved drugs, in which deuterium substitution has the
potential to enhance clinical safety, tolerability or efficacy.
Concert’s pipeline of
innovative medicines targets autoimmune diseases and central nervous
systems (CNS) disorders. For more information please visit www.concertpharma.com
or follow us on Twitter at @ConcertPharma
or on LinkedIn.

Cautionary Note on Forward Looking Statements
Any statements
in this press release about our future expectations, plans and
prospects, including statements about our expectations for clinical
development of CTP-543, and other statements containing the words
“anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,”
“intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,”
“target,” “would,” and similar expressions, constitute forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995. Actual results may differ materially from those
indicated by such forward-looking statements as a result of various
important factors, including: the uncertainties inherent in the
initiation of future clinical trials, whether preliminary results from a
clinical trial will be predictive of the final results of that trial or
whether results of early clinical trials will be indicative of the
results of later clinical trials, expectations for regulatory approvals,
availability of funding sufficient for our foreseeable and unforeseeable
operating expenses and capital expenditure requirements and other
factors discussed in the “Risk Factors” section of our most recent
Annual Report on Form 10-K filed with the Securities and Exchange
Commission and in other filings that we make with the Securities and
Exchange Commission. In addition, any forward-looking statements
included in this press release represent our views only as of the date
of this release and should not be relied upon as representing our views
as of any subsequent date. We specifically disclaim any obligation to
update any forward-looking statements included in this press release.

¹ Fricke M. Epidemiology and Burden of alopecia areata: a
systemic review. Clinical, Cosmetic and Investigational Dermatology.
2015; Vol 8. 397-403.

Concert Pharmaceuticals Inc., the CoNCERT Pharmaceuticals Inc. logo and
DCE Platform are registered trademarks of Concert Pharmaceuticals, Inc.
Jakafi® is a registered trademark of Incyte Corporation.

Contacts

Justine Koenigsberg (investors)
Concert Pharmaceuticals, Inc.
(781)
674-5284
[email protected]

Kathryn Morris (media)
The Yates Network
(914) 204-6412
[email protected]